Similar articles for PMID: 33833011

Year	Number of Results
2005	1
2007	1
2008	3
2009	1
2010	2
2011	2
2012	4
2013	4
2014	8
2015	15
2016	8
2017	17
2018	8
2019	12
2020	11
2021	14
2022	3

1

Management of Patients With Venous Thromboembolism After the Initial Treatment Period.

Fernandes TM, Kanwar M, White R. Fernandes TM, et al. J Am Board Fam Med. 2021 Mar-Apr;34(2):409-419. doi: 10.3122/jabfm.2021.02.200085. J Am Board Fam Med. 2021. PMID: 33833011 Free article. Review.

2

Optimal duration of anticoagulation. Provoked versus unprovoked VTE and role of adjunctive thrombophilia and imaging tests.

Prandoni P, Barbar S, Milan M, Campello E, Spiezia L, Piovella C, Pesavento R. Prandoni P, et al. Thromb Haemost. 2015 Jun;113(6):1210-5. doi: 10.1160/TH14-04-0396. Epub 2014 Aug 14. Thromb Haemost. 2015. PMID: 25119194 Review.

3

Anticoagulation in patients with isolated distal deep vein thrombosis: a meta-analysis.

Franco L, Giustozzi M, Agnelli G, Becattini C. Franco L, et al. J Thromb Haemost. 2017 Jun;15(6):1142-1154. doi: 10.1111/jth.13677. Epub 2017 Apr 18. J Thromb Haemost. 2017. PMID: 28316124 Free article.

4

Economic evaluation of strategies for restarting anticoagulation therapy after a first event of unprovoked venous thromboembolism.

Monahan M, Ensor J, Moore D, Fitzmaurice D, Jowett S. Monahan M, et al. J Thromb Haemost. 2017 Aug;15(8):1591-1600. doi: 10.1111/jth.13739. Epub 2017 Jul 11. J Thromb Haemost. 2017. PMID: 28520199 Free article.

5

Extended anticoagulation after venous thromboembolism: should it be done?

Fernandes CJ, Calderaro D, Piloto B, Hoette S, Jardim CVP, Souza R. Fernandes CJ, et al. Ther Adv Respir Dis. 2019 Jan-Dec;13:1753466619878556. doi: 10.1177/1753466619878556. Ther Adv Respir Dis. 2019. PMID: 31558116 Free PMC article. Review.

6

Empirical systemic anticoagulation is associated with decreased venous thromboembolism in critically ill influenza A H1N1 acute respiratory distress syndrome patients.

Obi AT, Tignanelli CJ, Jacobs BN, Arya S, Park PK, Wakefield TW, Henke PK, Napolitano LM. Obi AT, et al. J Vasc Surg Venous Lymphat Disord. 2019 May;7(3):317-324. doi: 10.1016/j.jvsv.2018.08.010. Epub 2018 Nov 23. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 30477976

7

The potential of target-specific oral anticoagulants for the acute and long-term treatment of venous thromboembolism.

Akwaa F, Spyropoulos AC. Akwaa F, et al. Curr Med Res Opin. 2014 Nov;30(11):2179-90. doi: 10.1185/03007995.2014.951425. Epub 2014 Aug 19. Curr Med Res Opin. 2014. PMID: 25105309 Review.

8

Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants.

Hillis C, Crowther MA. Hillis C, et al. Thromb Haemost. 2015 Jun;113(6):1193-202. doi: 10.1160/TH14-12-1036. Epub 2015 May 7. Thromb Haemost. 2015. PMID: 25948149 Review.

9

Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.

Coleman CI, Bunz TJ, Turpie AGG. Coleman CI, et al. Thromb Haemost. 2017 Oct 5;117(10):1841-1847. doi: 10.1160/TH17-03-0210. Epub 2017 Jun 22. Thromb Haemost. 2017. PMID: 28640322

10

Which patients are at high risk of recurrent venous thromboembolism (deep vein thrombosis and pulmonary embolism)?

Áinle FN, Kevane B. Áinle FN, et al. Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):201-212. doi: 10.1182/hematology.2020002268. Hematology Am Soc Hematol Educ Program. 2020. PMID: 33275736 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed